LRIG3
LRIG3 (Leucine-rich repeats and immunoglobulin-like domains protein 3) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Bladder & urothelial cancer, Lung cancer and Non-small-cell lung cancer.
Overview
May play a role in craniofacial and inner ear morphogenesis during embryonic development. May act within the otic vesicle epithelium to control formation of the lateral semicircular canal in the inner ear, possibly by restricting the expression of NTN1.
Open Targets scores its association with cancer at 0.63 (direct and indirect evidence; datatypes literature 0.91, genetic association 0.03, somatic mutation 0.82). IntOGen calls it a driver in 1 cohort (0 activating, 1 loss-of-function), covering Bladder Urothelial Carcinoma.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · LRIG3 (Leucine-rich repeats and immunoglobulin-like domains protein 3) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Bladder & urothelial cancer, Lung cancer and Non-small-cell lung cancer.
- 1 · What it is
LRIG3 (Leucine-rich repeats and immunoglobulin-like domains protein 3) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Bladder & urothelial cancer, Lung cancer and Non-small-cell lung cancer.
- 2 · What goes wrong in cancer
May play a role in craniofacial and inner ear morphogenesis during embryonic development.
- 3 · How drugs use it
No product in this corpus aims at LRIG3 yet. Because the protein is lost rather than overactive, drugs either restore its function or exploit the weakness its loss leaves (synthetic lethality).
External identifiers
Sources: HGNC HGNC:30991 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q6UXM1 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000139263 (association with cancer (MONDO_0004992) 0.63; per-cancer scores at or above 0.5: non-small cell lung carcinoma 0.53, lung cancer 0.55 (GraphQL API, CC0)); IntOGen LRIG3 (driver in 1 cohort (Act 0, LoF 1); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
May play a role in craniofacial and inner ear morphogenesis during embryonic development. May act within the otic vesicle epithelium to control formation of the lateral semicircular canal in the inner ear, possibly by restricting the expression of NTN1. Location: Cell membrane; Cytoplasmic vesicle membrane (UniProt). Locus 12q14.1 (HGNC).
- Bladder & urothelial cancer: IntOGen driver in 1 cohort (BLCA)
- Lung cancer: Open Targets association 0.55 with lung cancer (MONDO_0008903)
- Non-small-cell lung cancer: Open Targets association 0.53 with non-small cell lung carcinoma (MONDO_0005233)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it a loss-of-function (LoF) driver in 1 cohort. Evidence tier "cohort-driver" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"LRIG3" OR ABSTRACT:"LRIG3" OR TITLE:"leucine rich repeats and immunoglobulin like domains 3" OR ABSTRACT:"leucine rich repeats and immunoglobulin like domains 3" OR TITLE:"Leucine-rich repeats and immunoglobulin-like domains protein 3" OR ABSTRACT:"Leucine-rich repeats and immunoglobulin-like domains protein 3" OR TITLE:"FLJ90440" OR ABSTRACT:"FLJ90440" OR TITLE:"KIAA3016" OR ABSTRACT:"KIAA3016") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about LRIG3, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetCD74
Shares Lung cancer (all types), Open Targets Platform, Non-small-cell lung cancer.
- TargetSDC4
Shares Lung cancer (all types), Open Targets Platform, Non-small-cell lung cancer.
- TargetSLC34A2
Shares Lung cancer (all types), IntOGen, Open Targets Platform, Non-small-cell lung cancer.
- TargetIRS4
Shares Lung cancer (all types), Bladder & urothelial cancer, IntOGen, Open Targets Platform.
- TargetTFG
Shares Lung cancer (all types), IntOGen, Open Targets Platform.
- TargetRBM10
Shares Lung cancer (all types), Bladder & urothelial cancer, IntOGen, Open Targets Platform.
- TargetTPM3
Shares Lung cancer (all types), Open Targets Platform, Non-small-cell lung cancer.
- TargetEML4
Shares Lung cancer (all types), Open Targets Platform, Non-small-cell lung cancer.